Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer's disease

Transl Neurodegener. 2021 Feb 1;10(1):6. doi: 10.1186/s40035-021-00230-9.

Abstract

As the most common form of dementia, Alzheimer's disease (AD) is characterized by progressive cognitive impairments and constitutes a major social burden. Currently, the invasiveness and high costs of tests have limited the early detection and intervention of the disease. As a unique window of the brain, retinal changes can reflect the pathology of the brain. In this review, we summarize current understanding of retinal structures in AD, mild cognitive impairment (MCI) and preclinical AD, focusing on neurodegeneration and microvascular changes measured using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) technologies. The literature suggests that the impairment of retinal microvascular network and neural microstructure exists in AD, MCI and even preclinical AD. These findings provide valuable insights into a better understanding of disease pathogenesis and demonstrate that retinal changes are potential biomarkers for early diagnosis of AD and monitoring of disease progression.

Keywords: Alzheimer’s disease; Biomarkers; In vivo imaging; Mild cognitive impairment; Optical coherence tomography; Optical coherence tomography angiography; Retina.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / diagnostic imaging*
  • Biomarkers
  • Cognitive Dysfunction / diagnosis
  • Early Diagnosis
  • Humans
  • Middle Aged
  • Retina / diagnostic imaging*

Substances

  • Biomarkers